CLODERM Drug Patent Profile
Which patents cover Cloderm, and what generic alternatives are available?
Cloderm is a drug marketed by Legacy and is included in one NDA.
The generic ingredient in CLODERM is clocortolone pivalate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the clocortolone pivalate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cloderm
A generic version of CLODERM was approved as clocortolone pivalate by TARO on April 21st, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CLODERM?
- What are the global sales for CLODERM?
- What is Average Wholesale Price for CLODERM?
Summary for CLODERM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 43 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,842 |
| Drug Prices: | Drug price information for CLODERM |
| What excipients (inactive ingredients) are in CLODERM? | CLODERM excipients list |
| DailyMed Link: | CLODERM at DailyMed |
Recent Clinical Trials for CLODERM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Taro Pharmaceuticals USA | Phase 1 |
| WAYCro | Phase 1 |
| Promius Pharma, LLC | Phase 4 |
US Patents and Regulatory Information for CLODERM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legacy | CLODERM | clocortolone pivalate | CREAM;TOPICAL | 017765-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
